The use of cardiovascular system medicine in Sweden has shown a steady increase from 2013 to 2023, growing from 472.9 to 624.4 Defined Daily Doses (DDD) per thousand persons per day. The year-on-year growth has varied, reaching its highest at 4.86% in 2022. The compound annual growth rate (CAGR) over the past five years stands at 3.75%, indicating a robust upward trend.
Looking at the forecast from 2024 onwards, the use of cardiovascular medications is expected to continue its upward trajectory, with an anticipated increase to 749.8 DDD by 2028. The projected five-year CAGR from 2024-2028 is 2.89%, demonstrating a sustained demand for these medications.
Key future trends to watch for include:
- Innovations in cardiovascular medicine that could influence growth rates.
- Potential changes in healthcare policies and their impact on medicine use.
- Demographic shifts, particularly an aging population, driving increased demand.
- The advent of personalized medicine and its impact on prescription patterns.
